Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MIS416

Other · Immune activation, directed at nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and toll-like receptor 9 (TLR9) · developed by Innate Immunotherapeutics

Phase 2 Most advanced trial (none active)
IPHA Developer
1 Registered trials

What is MIS416?

MIS416 is a microparticle combining muramyl dipeptide and bacterial-derived DNA fragments from Propionibacterium acnes. It is taken up by monocytes and dendritic cells, where it binds and activates the innate pattern recognition receptors NOD2 and TLR9, stimulating cytokine and interferon secretion and immune cell activity. It is studied in secondary progressive multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Targets
nucleotide-binding oligomerization domain-containing protein 2 (NOD2), toll-like receptor 9 (TLR9)
Mechanism
Immune activation, directed at nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and toll-like receptor 9 (TLR9)
Pathways
NOD2 signaling, TLR9 signaling, interferon cytokine secretion, cytotoxic T lymphocyte response
Therapy area
Immunology
Developer
Innate Immunotherapeutics (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02228213 Phase 2 Secondary Progressive Multiple Sclerosis Completed IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Secondary Progressive Multiple Sclerosis

Other drugs acting on NOD2 / TLR9

More from Innate Immunotherapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind MIS416

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.